|
US2003143733A1
|
|
Tetrapeptide
|
|
AU2079900A
|
|
Inhibiting transforming growth factor beta to prevent accumulation of extracellular matrix
|
|
US6743892B1
|
|
Molecules that home to a selected organ in vivo
|
|
AU6374098A
|
|
Molecules that home to a selected organ or tissue in vivo and methods of identifying same
|
|
US5994501A
|
|
Tetrapeptide
|
|
US5916875A
|
|
Tetrapeptide
|
|
US6004748A
|
|
Method of inhibiting transcription utilizing nuclear receptors
|
|
CA2204535A1
|
|
Molecules that home to a selected organ or tissue in vivo and methods of identifying same
|
|
US5858972A
|
|
Antithrombotic agents and methods of use
|
|
US5622699A
|
|
Method of identifying molecules that home to a selected organ in vivo
|
|
US5817750A
|
|
Structural mimics of RGD-binding sites
|
|
US5747326A
|
|
Isolated nucleic acid molecules which encode mammalian α2,8 polysialyl transferases
|
|
AU2824195A
|
|
Nucleic acid molecules encoding human contactin
|
|
US5840555A
|
|
Transcriptional regulatory regions derived from the K18 gene
|
|
US5851994A
|
|
Compositions that inhibit wound contraction and methods of using same
|
|
US5677276A
|
|
Immobilization of peptides to hyaluronate
|
|
US5695997A
|
|
Tetrapeptide
|
|
US5780303A
|
|
Method and composition for treating thrombosis
|
|
US6180610B1
|
|
Tetrapeptide
|
|
US5648330A
|
|
Method and composition for treating vascular graft occlusion
|
